Last reviewed · How we verify
WX390
At a glance
| Generic name | WX390 |
|---|---|
| Also known as | WXFL10030390 |
| Sponsor | Shanghai Jiatan Pharmatech Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment (PHASE3)
- A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations (PHASE2)
- A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- A Study of WX390 in Patients With Advanced Solid Tumors (PHASE2)
- A Study of WX390 in Patients With Advanced Solid Tumors With PIK3CA Mutations (PHASE1, PHASE2)
- A Study of WXFL10030390 in Patients With Advanced Solid Tumors or Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- WX390 CI brief — competitive landscape report
- WX390 updates RSS · CI watch RSS
- Shanghai Jiatan Pharmatech Co., Ltd portfolio CI